Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD19 + anti-BCMA CAR-T cells
- Development stage
- Phase 1
- Lead developer
- Chinese PLA General Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**Anti-CD19 + anti-BCMA CAR-T cells** are autologous T cells genetically engineered to express a bispecific chimeric antigen receptor (CAR) targeting both CD19 and B-cell maturation antigen (BCMA). This second-generation CAR therapy, often incorporating a 4-1BB costimulatory domain, enables T cells to recognize and eliminate malignant plasma cells expressing BCMA and a subset of less-differentiated myeloma cells expressing low levels of CD19, addressing antigen escape seen in single-target therapies. Primarily developed for relapsed/refractory multiple myeloma (R/R MM), clinical trials (e.g., Phase I/II) report high overall response rates (92%), complete response rates (62%), median progression-free survival of 19.7 months, and a favorable safety profile with manageable cytokine release syndrome.
- Other names
- bispecific BCMA/CD19 CAR T cellsdual-target BCMA/CD19 CAR T cells19BC CAR T cells
02
Targets
CD19 (B lymphocyte antigen CD19)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on anti-CD19 + anti-BCMA CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD19 + anti-BCMA CAR-T cells.